Long‐term evolution of multiple sclerosis disability in the treatment era
Top Cited Papers
Open Access
- 27 July 2016
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 80 (4), 499-510
- https://doi.org/10.1002/ana.24747
Abstract
Objective To characterize the accrual of long-term disability in a cohort of actively treated multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance imaging (MRI) data used in clinical trials have long-term prognostic value. Methods This is a prospective study of 517 actively managed MS patients enrolled at a single center. Results More than 91% of patients were retained, with data ascertained up to 10 years after the baseline visit. At this last assessment, neurologic disability as measured by the Expanded Disability Status Scale (EDSS) was stable or improved compared to baseline in 41% of patients. Subjects with no evidence of disease activity (NEDA) by clinical and MRI criteria during the first 2 years had long-term outcomes that were no different from those of the cohort as a whole. 25-OH vitamin D serum levels were inversely associated with short-term MS disease activity; however, these levels had no association with long-term disability. At a median time of 16.8 years after disease onset, 10.7% (95% confidence interval [CI] = 7.2–14%) of patients reached an EDSS ≥ 6, and 18.1% (95% CI = 13.5–22.5%) evolved from relapsing MS to secondary progressive MS (SPMS). Interpretation Rates of worsening and evolution to SPMS were substantially lower when compared to earlier natural history studies. Notably, the NEDA 2-year endpoint was not a predictor of long-term stability. Finally, the data call into question the utility of annual MRI assessments as a treat-to-target approach for MS care. Ann Neurol 2016;80:499–510Funding Information
- National Institutes of Health (RO1NS26799, RO1NS026799, K23 NS067055)
- University of California, San Francisco
This publication has 54 references indexed in Scilit:
- Spinal cord gray matter atrophy correlates with multiple sclerosis disabilityAnnals of Neurology, 2014
- Disease Activity Free StatusJAMA Neurology, 2014
- Predictors of long‐term outcome in multiple sclerosis patients treated with interferon betaAnnals of Neurology, 2013
- Progressive multiple sclerosis: pathology and pathogenesisNature Reviews Neurology, 2012
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Natural history of multiple sclerosis in a population‐based cohortEuropean Journal of Neurology, 2008
- Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosisMultiple Sclerosis Journal, 2008
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 2001
- Defining the clinical course of multiple sclerosisNeurology, 1996